Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.62 |
| ▸ | S1PR3 | Q99500 | 18/20 | 0.62 |
| ▸ | S1PR5 | Q9H228 | 10/20 | 0.62 |
| ▸ | S1PR4 | O95977 | 9/20 | 0.62 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4821435 | 0.88 | S1PR1 (0.76) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL4825689 | 0.87 | S1PR1 (0.78) | S1PR1S1PR3S1PR5S1PR4S1PR2 | |
| SCHEMBL13614241 | 0.87 | S1PR1 (0.64) | S1PR1S1PR3S1PR5S1PR4S1PR2 | |
| SCHEMBL1362980 | 0.86 | S1PR1 (0.52) | S1PR1S1PR3S1PR5S1PR4S1PR2 | |
| SCHEMBL4821551 | 0.86 | S1PR1 (0.80) | S1PR1S1PR3S1PR5S1PR4S1PR2 | |
| SCHEMBL385619 | 0.85 | S1PR1 (0.54) | S1PR1S1PR3S1PR5S1PR4S1PR2 | |
| SCHEMBL386475 | 0.85 | S1PR1 (0.54) | S1PR1S1PR3S1PR5S1PR4S1PR2 | |
| SCHEMBL385072 | 0.84 | S1PR1 (0.53) | S1PR1S1PR3S1PR5S1PR4S1PR2 | |
| SCHEMBL385845 | 0.83 | S1PR1 (0.62) | S1PR1S1PR3S1PR5S1PR4S1PR2 | |
| SCHEMBL5402160 | 0.81 | S1PR1 (0.71) | S1PR1S1PR3S1PR5S1PR4S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612238-B2 | Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |